A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

被引：0
|
作者：
Gort, Eelke
Johnson, Melissa Lynne
Hwang, Jimmy J.
Pant, Shubham
Dunzinger, Ulrich
Riemann, Kathrin
Kitzing, Thomas
Janne, Pasi A.
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Biberach, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3651
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    Investigational New Drugs, 2013, 31 : 409 - 416
  • [32] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [33] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [34] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [35] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
    Tolcher, Anthony W.
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony G.
    Lahmar, Mehdi
    Wang, Bushi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
    Eskens, F.
    Oldenhuis, C. N.
    Bhargava, P.
    Loos, W.
    Esteves, B.
    van Doorn, L.
    Cotreau, M. M.
    Dhillon, R.
    Gietema, J. A.
    De Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [38] Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
    Sausville, E. A.
    LoRusso, P.
    Carducci, M. A.
    Barker, P. N.
    Agbo, F.
    Oakes, P.
    Senderowicz, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
    Daud, Adil I.
    Ashworth, Michelle T.
    Strosberg, Jonathan
    Goldman, Jonathan W.
    Mendelson, David
    Springett, Gregory
    Venook, Alan P.
    Loechner, Sabine
    Rosen, Lee S.
    Shanahan, Frances
    Parry, David
    Shumway, Stuart
    Grabowsky, Jennifer A.
    Freshwater, Tomoko
    Sorge, Christopher
    Kang, Soonmo Peter
    Isaacs, Randi
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1060 - +
  • [40] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Liu, Rui
    Deng, Ting
    Bai, Ming
    Zhang, Le
    Ning, Tao
    Wang, Xia
    Ji, Zhi
    Yang, Yuchong
    Ge, Shaohua
    Li, Hongli
    Duan, Jingjing
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345